Oragenics (OGEN) Total Liabilities (2010 - 2026)
Oragenics' (OGEN) quarterly Total Liabilities came in at $1.3 million in Q1 2026, down 64.95% YoY from $3.7 million in Q1 2025, and down 26.79% on a QoQ basis from $1.8 million in Q4 2025.
Oragenics (OGEN) Total Liabilities (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Total Liabilities data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Total Liabilities fell 64.95% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 64.95% YoY) and the FY2025 annual result came in at $1.8 million, up 6.05% from the prior year.
- Total Liabilities slipped to $1.3 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $23.6 million in Q1 2022 to a low of $908686.0 in Q1 2024.
- A 5-year average of $7.4 million and a median of $3.7 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities sank 92.51% — and 2025, when it jumped 310.64%.
- Tracing OGEN's Total Liabilities over 5 years: stood at $14.8 million in 2022, then tumbled by 87.82% to $1.8 million in 2023, then fell by 6.33% to $1.7 million in 2024, then grew by 6.05% to $1.8 million in 2025, then declined by 26.79% to $1.3 million in 2026.
- The last three Total Liabilities figures came in at $1.3 million (Q1 2026), $1.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | 2.87 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 908,686.00 |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 7.90 Mn |
| Jun 30, 2023 | 8.46 Mn |
| Mar 31, 2023 | 12.13 Mn |
| Dec 31, 2022 | 14.76 Mn |
| Sep 30, 2022 | 17.05 Mn |
| Jun 30, 2022 | 20.35 Mn |
| Mar 31, 2022 | 23.65 Mn |
| Dec 31, 2021 | 28.23 Mn |
| Sep 30, 2021 | 31.09 Mn |